|
| IL-22在初诊急性髓系白血病患者中的表达及其对预后的影响 |
| The significance of serum IL-22 level in patients with acute myeloid leukemia |
| 投稿时间：2025-05-23 修订日期：2026-01-19 |
| DOI： |
| 中文关键词: 急性髓系白血病；血清IL-22；MRD; CR；DFS。 |
| 英文关键词: Acute myeloid leukemia, Serum IL-22, CR, DFS. |
| 基金项目: |
| 作者 | 单位 | 邮编 | | 宫暖燕 | 滨州医学院基础医学院免疫室 | 264003 | | 韦若颍 | 济南市儿童医院 | | | 傅甜 | 滨州医学院基础医学院免疫室 | | | 吴沄桦 | 滨州医学院基础医学院免疫室 | | | 毕可红 | 山东第一医科大学（山东省医学科学院）第一附属医院（山东省千佛山医院） | | | 姜国胜* | 滨州医学院基础医学院免疫室 | 264003 |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：检测急性髓系白血病AML(Acute myeloid leukemia,AML)患者血清IL-22(Interleukin-22,IL-22)水平，并探讨其变化的临床意义。方法：采用ELISA测定血清IL-22水平，ROC曲线法确定AML患者和正常对照组血清IL-22临界值，统计分析各组间的IL-22水平差异，以及IL-22水平与临床疗效之间的关系。结果：1、不同AML患者组的血清IL-22水平比较后，发现AML患者组高于对照组（t=4.622, P<0.0001），复发组和未复发组，或者完全缓解（CR）组和未缓解（NR）组之间均没有明显差异（（t=1.793,P=0.0807；t=1.898,P=0.0625），微小残留病（MRD）阳性组高于MRD阴性组（t=2.084,P=0.0413）。2、血清IL-22大于临界值与小于临界值组比较后，大于临界值组的无病生存期（DFS）降低（t=3.845，P=0.0003），复发率升高（P<0.0001），MRD率升高（P<0.0001），5年生存率降低（P=0.0014）。而大于和小于临界值两组的CR率差异不明显（P=0.5893）。3、CR组、MRD阴性和血清IL-22小于等于临界值组的无病生存期显著延长（χ2=5.944，P=0.015；χ2=20.431，P<0.001；χ2=36.955，P<0.001）。Cox多因素回归分析后，血清IL-22水平>25pg/mL患者的无病生存期显著低于血清IL-22水平≤25pg/mL的患者组（P<0.001）。而年龄、性别、外周血白细胞总数（WBC)、淋巴细胞总数、MRD、融合基因、核型和基因突变等因素，并没有明显影响患者的无病生存期（P>0.05)。结论：AML患者血清IL-22水平高于对照组，血清IL-22水平是AML预后的独立危险因素。 |
| 英文摘要: |
| Objective: To detect the level of serum IL-22(Interleukin-22,IL-22) in patients with acute myeloid leukemia AML(Acute myeloid leukemia,AML)，and analyze its clinical significance. Methods: Serum IL-22 levels were measured by ELISA, and the critical value of serum IL-22 in AML patients and control group was determined by ROC curve method. Statistical analysis was performed on the difference of IL-22 levels between different groups, and the relationship between IL-2 levels and clinical efficacy. Result: 1.Comparison of the serum IL-22 levels in different AML patient groups revealed higher levels in AML patients than in control group (t=.622, P<0.0001), with no significant differences between the relapse and non-relapse groups, or between the complete remission (CR) and non-remission (NR) groups (t=1.793,P=0.0807; t=1.89,P=0.0625), but higher levels in the MRD positive group than in the MRD negative group (t=2084,P=0.0413). 2.Compared with the group with serum IL-22 below the critical value, the disease-free survival (DFS) rate was lower (t=3.845, P=0.0003), the recurrence rate and MRD rate was higher (P<0.0001; P<0.0001), the 5-year survival rate was lower (P=0.0014). And the difference of CR rate between the two groups greater than and less than the critical value was not obvious (P = 0.5893). 3、The disease-free survival time was significantly prolonged in the CR group, MRD negative group and the group with serum IL-22 less or equal to the critical value (χ2=5.944, P=0.015; χ2=20.431, P<0.001; χ2=36.955, P<0.001). After Cox multivariate regression analysis, the-free survival time of the patients with serum IL-22 level >25pg/mL was significantly lower than that of the patients with serum IL-22 level 25pg/mL (P<0.001). However, age, gender, peripheral white blood cell total (WBC), lymphocyte, MRD, fusion gene, karyotype and gene mutation and other factors did not significantly affect the disease-free survival time of patients (P>0.05). Conclusion: Serum IL-22 levels were higher in AML patients than in the control group, and the level of serum IL-22 was an independent risk for the prognosis of AML. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
|
|
|
